Ascendis Pharma A/S (ASND)
NASDAQ: ASND · IEX Real-Time Price · USD
141.01
+2.57 (1.86%)
May 1, 2024, 4:00 PM EDT - Market closed
Ascendis Pharma Employees
Ascendis Pharma had 879 employees on December 31, 2023. The number of employees increased by 82 or 10.29% compared to the previous year.
Employees
879
Change (1Y)
82
Growth (1Y)
10.29%
Revenue / Employee
$337,148
Profits / Employee
-$608,579
Market Cap
7.98B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 879 | 82 | 10.29% |
Dec 31, 2022 | 797 | 158 | 24.73% |
Dec 31, 2021 | 639 | 157 | 32.57% |
Dec 31, 2020 | 482 | 152 | 46.06% |
Dec 31, 2019 | 330 | 114 | 52.78% |
Dec 31, 2018 | 216 | 79 | 57.66% |
Dec 31, 2017 | 137 | 36 | 35.64% |
Dec 31, 2016 | 101 | 23 | 29.49% |
Dec 31, 2015 | 78 | 23 | 41.82% |
Dec 31, 2014 | 55 | 10 | 22.22% |
Dec 31, 2013 | 45 | 7 | 18.42% |
Dec 31, 2012 | 38 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Encompass Health | 37,761 |
Chemed | 15,087 |
Bio-Rad Laboratories | 8,030 |
Bio-Rad Laboratories | 8,030 |
Stevanato Group | 5,634 |
Penumbra | 4,200 |
Legend Biotech | 1,826 |
Inspire Medical Systems | 1,011 |
ASND News
- 6 days ago - Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024 - GlobeNewsWire
- 7 days ago - United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism - GlobeNewsWire
- 21 days ago - This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives? - Market Watch
- 2 months ago - Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024 - GlobeNewsWire
- 3 months ago - Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results - GlobeNewsWire
- 3 months ago - Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 3 months ago - Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024 - GlobeNewsWire
- 3 months ago - Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism - GlobeNewsWire